生物学的製剤API(原薬)製造サービスの世界市場予測2016-2026

◆英語タイトル:Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026
◆商品コード:VGAIN81916
◆発行会社(調査会社):visiongain
◆発行日:2016年8月
◆ページ数:238
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、生物学的製剤API(原薬)製造サービスの世界市場について調査・分析し、生物学的製剤API(原薬)製造サービスの世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. バイオテクノロジーAPI製造サービスの概要

3. バイオテクノロジーAPI製造サービス:世界市場見通し・予測

4. バイオテクノロジーAPI製造サービス2次市場:世界市場見通し・予測

5. バイオテクノロジーAPI製造:主要な生物学的製剤API受託製造セクター見通し

6. 主要国のバイオテクノロジーAPI受託製造サービス市場

7. バイオテクノロジーAPI製造サービス市場における主要CMO

8. バイオテクノロジーAPI製造サービス市場動向:定性分析

9. 調査インタビュー

10. 結論

【レポートの概要】

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2015 to 2026 for the biotech API manufacturing services market, as well as for therapeutic applications.

How this 238 page report delivers:

• Provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
– Mammalian cell culture
– Microbial fermentation
– Other expression platforms

• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
– Monoclonal antibody (mAb) therapies
– Vaccines
– Insulin therapies
– Interferon therapies
– Growth hormones

• Find forecasts of the leading therapeutic and national markets from 2015 to 2026:
– The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
– The US
– Japan
– Switzerland
– Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
– Boehringer Ingelheim BioXcellence
– Celltrion
– DSM Biologics
– Lonza
– Samsung BioLogics
– Cytovance Biologics
– Fujifilm Diosynth Biotechnologies
– Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2016, as well as predicted developments for the period to 2026.
• Read expert opinions from other authorities on the biotech API manufacturing industry.
• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2016. The report also contains SWOT and STEP analysis of the industry and market.
• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

How This Report Delivers: Chapter Summary
This updated study provides an overview of the subject along with qualitative and quantitative analyses of the biotech API manufacturing services market. This report contains expert opinions from industry participants. In more detail, the chapters of this report contain the following information:

Chapter 1 forms a report overview.

Chapter 2 defines the biotech API manufacturing services market and provides an introduction to that industry.

Chapter 3 quantitatively assesses the world market for biotech API manufacturing services revenues. The chapter provides an estimate for the size of the market in 2015 and forecasts revenues for the period 2015-2026. Visiongain discusses the main drivers and restraints on the market for a 10-year forecast period.

Chapter 4 provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
• Mammalian cell culture
• Microbial fermentation
• Other expression platforms.

For the leading submarkets, we analyse commercial drivers and restraints, as well as forecasting revenues to 2026.

Chapter 5 provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones.

Chapter 6 forecasts the leading national submarkets for biotech API manufacturing services, for the period 2015-2026. That section also provides quantitative analysis. The chapter offers a regional breakdown of the market by market share, and also discusses developments and future expectations for each main national submarket. National submarkets forecasted in this chapter are these:
• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
• Japan
• Switzerland
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

Chapter 7 profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
• Boehringer Ingelheim BioXcellence
• Celltrion
• DSM Biologics
• Lonza
• Samsung BioLogics
• Cytovance Biologics
• Fujifilm Diosynth Biotechnologies
• Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

Chapter 8 provides qualitative analysis of the biotech API manufacturing services market from 2015. That chapter identifies main strengths and weaknesses of the market, as well as opportunities and threats facing CMOs to 2026. Social, technological, economic and political (STEP) factors affecting market growth are also discussed. Industry trends and regulatory developments affecting the market are discussed.

Chapter 9 provides transcripts of interviews conducted by visiongain with other authorities. For this report, visiongain interviewed the following authorities on the CMO industry:
• Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies, UK.
• Jon S. Gingrich, Manager of Business Development, Avid Bioservices Inc., US.

Chapter 10 summarises the report, highlighting conclusions from visiongain’s research and analysis.

【レポートの目次】

1. Report Overview
1.1 Contract Biotech API Manufacturing: World Market Review 2016
1.2 Benefits of this Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by This Analytical Report
1.3 Who is This Report For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Some Associated Reports
1.7 About Visiongain

2. Introduction to Biotech API Manufacturing Services
2.1 What are Biotech API Manufacturing Services?
2.1.1 Producing Biotech API: An Overview of the Manufacturing Process
2.1.2 Defining the Biotech API Manufacturing Market
2.1.3 Differing Expression Systems to Manufacture APIs
2.2 Challenges in Manufacturing Biotech API
2.3 Outsourcing: A Common Trend in Biotech API Manufacturing Services
2.4 Future Trends for the Biotech API Manufacturing Services Market
2.5 Glossary

3. Biotech API Manufacturing Services: World Market Outlook and Forecast 2016-2026
3.1 The Contract Biotech API Manufacturing Services Market Performance, 2016
3.1.1 Contract Biotech API Manufacturing Services: Forecast 2015-2026
3.2 Drivers and Restraints in the Biotech API Manufacturing Services Market
3.2.1 Important Drivers in the Biotech API Manufacturing Services Market for the Coming Decade
3.2.1.1 The Ageing Population is a Driver for Growth
3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
3.2.1.3 Outsourcing as a Driver for Growth
3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
3.2.1.5 Increased Investment in Orphan Drugs from Companies
3.2.1.6 Emerging Markets Will Grow and Influence the Market
3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
3.2.2 Restraints on Growth in the Biotech API Manufacturing Services Market
3.2.2.1 Pricing Pressures Will Limit Market Growth
3.2.2.2 Regulatory Restrictions Will Increase
3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
3.2.2.4 Complexity of API Production is a Challenge
3.3 Outlook for the Outsourced Biotech API Services: Increased Demand

4. Biotech API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2016-2026
4.1 Submarkets for the Biotech API Manufacturing Services Industry
4.1.1 The Mammalian Cell Culture Submarket
4.1.2 The Mammalian Cell Culture Submarket Forecast 2015-2026
4.1.3 ADCs and Next-Generation Antibodies Will Drive Growth 2015-2026
4.1.4 The Microbial Fermentation Submarket
4.1.5 The Microbial Fermentation Submarket Forecast 2015-2026
4.1.5.1 Increase in Demand for Insulin Will Drive Growth 2015-2026
4.1.6 Other APIs Expression Systems Are Still in Development
4.1.6.1 Plant-Made Pharmaceuticals
4.1.6.2 Yeast Cell Expression Systems
4.1.6.3 Insect Cell Expression Systems
4.1.6.4 Other Expression Systems Submarket Forecast 2015-2026
4.2 Chapter Summary: Positive Growth for the Market

5. Biotech API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2015-2026
5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2015-2026
5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
5.2.1 Contract API Vaccine Market: Outlook and Forecast 2015-2026
5.2.2 Challenges in Manufacturing Vaccines
5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
5.3.1 Contract API Insulin Analogues Forecast 2015-2026
5.3.2 Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
5.3.3 Development Trends in the Contract API Insulin Market to 2026
5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
5.4.1 Contract API Interferon Market Forecast 2015-2026
5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
5.5.1 Contract API Growth Hormone Market Forecast 2015 to 2026
5.5.2 Most Manufacturing is In-House for Growth Hormone Production
5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
5.6 Chapter Summary: Outsourcing for Key Biological Products 2015-2026

6. Leading National Markets for Contract Biotech API Manufacturing Services 2015-2026
6.1 Regional Breakdown of the World Biotech API Manufacturing Services Market
6.1.1 US and EU Dominate Growth for Leading National Submarkets 2015-2026
6.1.2 National Revenue Shares by 2026: Emerging Market Growth
6.2 Contract Biotech API Manufacturing in EU Market 2015-2026
6.2.1 Strong Growth for the EU Revenue Forecasts 2015-2026
6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2015-2026
6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
6.2.2.3 France: Strong Vaccine Development Industry
6.2.2.4 Switzerland: Headquarters for Leading Companies
6.2.2.4.1 Switzerland: Headquarters for Leading Companies
6.2.2.5 Spain: Numerous Biotech Companies
6.2.2.6 Italy: Outlook and Forecast 2015-2026
6.2.3 US: A Market Leader in Biotech API Manufacturing
6.2.4 Japan: A Less Mature Contract Manufacturing Market
6.2.5 BRIC Market: Outlook and Forecasts for Emerging Markets 2015- 2026
6.2.5.1 Emerging Nations May Develop a Presence in the Biologics Market
6.2.5.2 Increased Demand for Biosimilars and Biological Drugs 2015-2026
6.2.5.3 China is Poised for Growth: Forecast for 2015-2026
6.2.5.4 India Offers a Lower-Cost Advantage for Biotech API Manufacturing Services: Forecast 2015-2026
6.2.5.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
6.2.5.6 Russian Biotech API Manufacturing Services Forecast: 2015-2026
6.2.5.7 Brazilian Biotech API Manufacturing Services Forecast: 2015-2026
6.2.6 South Korea: Market Forecast, 2015-2026
6.2.6.1 Leading CMOs Celltrion and Samsung BioLogics Drive the Market
6.2.7 Singapore: Market Forecast, 2015-2026
6.3 Summary of Chapter: Outlook for Leading National Submarkets 2015-2026

7. Leading CMOs in the Biotech API Manufacturing Services Market 2016
7.1 Four Companies Led the Market in 2015
7.2 Leading Companies by Capacity
7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
7.2.2 Barriers to Market Entry 2015-2026
7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
7.3 FDA Opens Barriers for the Biosimilars Market
7.4 Boehringer Ingelheim BioXcellence
7.4.1 Strategic Outlook: Expanding into the Asian Market
7.5 Celltrion: Biologics Leader in Asia
7.5.1 Celltrion: Likely Target for Mergers and Acquisitions?
7.6 DSM Biologics: Strategically Increasing Capacity
7.7 Lonza Has the Largest Worldwide Cell Culture Capacity
7.7.1 Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
7.8 Other Market Players of Interest in 2016
7.8.1 Samsung BioLogics: Focusing on Biosimilars
7.8.2 Cytovance Biologics: Plans to Expand
7.8.3 Fujifilm Diosynth Biotechnologies
7.8.3.1 Facility and Service Expansion for the Future
7.9 Leading Biopharma Companies Operate CMO Divisions
7.9.1 AbbVie Contract Manufacturing: Strength through Acquisition
7.9.2 GSK Biopharmaceuticals
7.9.3 Sandoz: Expertise in Biologics and Biosimilars
7.9.4 Rentschler Biotechnologie: Recent Expansions
7.10 Teva: A Future Player in the Biologics Market
7.11 Catalent Offers a New Platform through Partnership
7.12 Chapter Summary: Leading Companies 2015-2026

8. Biotech API Manufacturing Services Market Industry Trends 2015-2026: Qualitative Analysis
8.1 SWOT Analysis: Strengths and Weaknesses of the Biotech API Manufacturing Services Market 2016
8.1.1 Biopharmaceutical Demand for Outsourcing is Increasing
8.1.2 A Fragmented Market with a Costly and Difficult Manufacturing Process
8.2 Opportunities for the Biotech API Manufacturing Services Market 2015-2026
8.3 Threats for the Biotech API Manufacturing Services Market 2015-2026
8.4 STEP Analysis of the Biotech API Manufacturing Services Market
8.4.1 Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
8.4.2 Technological Factors: Advances Will Drive Growth
8.4.2.1 Single-Use Technology: A Vital Trend for the Future
8.4.3 Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
8.4.4 Political Factors: Regulatory Requirements Need to Be Met
8.5 Trends in Biological Drug Development 2015-2026
8.5.1 Biosimilars Will Be an Important Opportunity for CMOs
8.5.2 CMOs are Investing in Next-Generation Antibody Development
8.5.3 Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
8.5.4 Outlook for Single-Use Technologies in Biotech API Manufacturing 2015-2026
8.5.4.1 Future Direction: Single-Use Systems Will be Essential
8.5.5 Outsourcing Trends for Biotech API Manufacturing 2015-2026
8.5.5.1 Biopharma Companies Continue to Invest in In-House Facilities
8.5.5.2 Off-shoring Biotech API Manufacturing to Emerging Markets: Not a Trend for this Decade?
8.5.5.3 Overcapacity is a Risk for the Biotech CMO Industry
8.5.5.4 Future Trends: Strategic Partnering
8.5.5.5 Alternative Expression Methods
8.6 Regulations and Effects on the Biotech API Manufacturing Services Industry
8.6.1 Effect on the Emerging Biotech API Manufacturing Services Market 2015-2026
8.6.2 Regulations in Other Countries in the Biotech API Market
8.7 Chapter Summary: Industry Trends for Contract Biotech API Manufacturing to 2026

9. Research Interviews
9.1 Interview with Mr Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies (Fujifilm)
9.1.1 Novel Expression Platforms
9.1.2 Expanding Manufacturing Capacity
9.1.3 Acquisition of KalonBiotherapeutics – Effects on Business?
9.1.4 Over-capacity – A Realistic Threat to API Manufacturing CMOS?
9.1.5 Future Opportunities for the API Manufacturing CMO Market
9.2 Interview with Mr Jon S. Gingrich, Manager, Business Development, Avid Bioservices Inc., California, USA
9.2.1 Avid Bioservices
9.2.2 The Influence of Biosimilars on the Current Biotech API Manufacturing Services Market for CMOs
9.2.3 Competition in the US Biotech API Manufacturing Services Market
9.2.4 The Challenges of API Manufacturing
9.2.5 Avid Bioservices Strategies for Growth in the Biotech API Manufacturing Services Market

10. Conclusions
10.1 The Contract Biotech API Manufacturing Services Market
10.2 Outlook for the Biotech API Manufacturing Services Market
10.2.1 Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biotech API Manufacturing
10.2.2 The US and EU Markets Lead for the Global Biotech API Manufacturing Services Market in 2015
10.2.3 Single-Use Technology Will Become Indispensable for Success in the Market
10.3 Growth in the Market 2015-2026
10.3.1 The Future of the Biotech API Manufacturing Services Marketplace

List of Tables
Table 1.1: Redacted Submarket Forecast : Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2015-2026
Table 2.1 Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2015
Table 3.1 Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2015-2020
Table 3.1.1 Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2021-2026
Table 4.1 Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR(%), CAGR(%), 2015-2020
Table 4.1.1 Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR(%), CAGR(%), 2020-2026
Table 4.2 ADC Pipeline 2016
Table 4.3 Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR(%), CAGR(%), 2015-2020
Table 4.3.1 Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR(%), CAGR(%), 2021-2026
Table 4.4 Selected CMOs Investing in Biological API Manufacturing Capacity, 2016
Table 4.5 Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.5.1 Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2021-2026
Table 4.6 Other Expression Systems Submarket Two Year Forecast Revenues ($bn), AGR (%), 2015-2026
Table 5.1 Top Ten Best-Selling Drugs in 2015: Revenue ($bn)
Table 5.2 Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Therapeutic Area, 2015-2020
Table 5.3 Leading Contract API Biological Drug Revenue Forecasts ($bn) AGR (%), CAGR (%), by Therapeutic Area, 2020-2026
Table 5.4 Monoclonal Antibody Types and Sources
Table 5.5 Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 5.5.1 Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 5.6 The Four Classes of Next- Generation Antibody Therapies
Table 5.7 Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2015-2020
Table 5.7.1 Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2020-2026
Table 5.8 Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2015-2020
Table 5.8.1 Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2021-2026
Table 5.9 Interferon Therapies Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 5.9.1 Interferon Therapies Market: Contract API Revenue Forecast ($bn), ), CAGR (%), AGR (%), 2020-2026
Table 5.10 Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 5.10.1 Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2020-2026
Table 5.11 Selected Long-Acting Growth Hormones in Development, 2016
Table 6.1 Contract Biotech API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2015
Table 6.2 Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.3.1 Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.4 Contract Biotech API Manufacturing Market: National Revenue Two Year Shares (%), 2016-2026
Table 6.5 EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2015-2020
Table 6.5.1 EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2021-2026
Table 6.6 EU and Switzerland Contract Biotech API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2015
Table 6.7 German Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2015-2026
Table 6.7.1 German Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2015-2026
Table 6.8 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2015-2020
Table 6.8.1 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2021-2026
Table 6.9 French Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2015-2020
Table 6.9.1 French Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2021-2026
Table 6.10 Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.10.1 Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.11 Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2015-2020
Table 6.11.1 Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2020-2026
Table 6.12 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.12.1 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.13 US Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.13.1 US Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.14 Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.14.1 Japanese Contract Biotech API Manufacturing Revenue Forecast, CAGR (%), AGR (%), ($bn),2021-2026
Table 6.15 Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.15.1 Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.16 BRIC Markets: API Revenues ($bn) and Market Shares (%), 2015
Table 6.17 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.17.1 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.18 Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%) 2015-2020
Table 6.18.1 Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.19 Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.19.1 Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.20 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.20.1 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.21 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.21.1 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 6.22 Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2015
Table 6.23 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
Table 6.23.1 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
Table 7.1 Leading Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
Table 7.2 Selected Other Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
Table 7.3 Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2015
Table 7.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2013-2015
Table 7.5 Celltrion: Revenue ($bn), CAGR (%), AGR (%), 2009-2015
Table 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), CAGR (%), AGR (%), 2009-2015
Table 7.7 Lonza: New Biological Drug Sector Manufacturing Agreements, 2015
Table 7.8 Sandoz Biosimilar Pipelines: Selected Biosimilars, 2016
Table 8.1 Contract Biotech API Manufacturing Market: Strengths and Weaknesses, 2015-2016
Table 8.2 Contract Biotech API Manufacturing Market: Opportunities and Threats, 2015-2026
Table 8.3 Biotech API Manufacturing Services Market: STEP Analysis, 2016
Table 8.4 Selected EU-Approved Biosimilars: Manufacturers and Companies, 2015
Table 8.5 Approved Next-Generation Antibody Therapies, 2015
Table 10.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2016, 2018, 2020, 2022, 2024 and 2026
Table 10.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2016, 2018, 2020, 2022, 2024 and 2026

List of Figures
Figure 1.1 Biological Drug API Manufacturing Services Submarkets 2016
Figure 2.1 Steps for Biological Drug Manufacturing, 2016
Figure 2.2 Contract API Manufacturing: Market Shares by Sector (%), 2015
Figure 2.3 Future Trends in the Biotech API Manufacturing Market, 2016-2026
Figure 3.1 Contract Biotech API Manufacturing Services Market: Revenue Forecast ($bn), AGR (%), 2016-2026
Figure 3.2 Contract Biotech API Manufacturing: Market Drivers, 2016-2026
Figure 3.3 Contract Biotech API Manufacturing: Market Restraints, 2016-2026
Figure 4.1 Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2015
Figure 4.2 Mammalian Cell Culture Submarket Forecast, Revenue ($bn), AGR(%), 2015-2026
Figure 4.3 Mammalian Cell Culture Submarket: Drivers and Restraints, 2015-2026
Figure 4.4 Microbial Fermentation Submarket Forecast($bn), AGR (%), 2015-2026
Figure 4.5 Microbial Fermentation Submarket: Drivers and Restraints, 2016
Figure 4.6 Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2015-2020
Figure 4.6.1 Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2021-2026
Figure 5.1 Leading Contract API Biological Drug by Sector, 2015
Figure 5.2 Monoclonal Antibody Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
Figure 5.3 Vaccines Market: Contract API Revenues Forecast ($bn), AGR(%) 2015-2026
Figure 5.3.1 Comparison between biomanufacturing platforms for Vaccine production: VLP
Figure 5.4 Insulin Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
Figure 5.5 Interferon Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
Figure 5.6 Growth Hormones Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
Figure 6.1 Contract Biotech API Manufacturing: Market Shares by Region (%), 2016
: Market Shares by Region (%), 2014
Figure 6.2 Contract Biotech API Manufacturing: Market Shares by Region (%) 2020
Figure 6.3 Contract Biotech API Manufacturing: Market Shares by Region (%) 2025
Figure 6.4 EU and Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.5 EU Contract Biotech API Manufacturing: Leading National Revenue Shares (%), 2015
Figure 6.6 German Contract Biotech API Manufacturing Revenue Forecast ($bn), 2015-2026
Figure 6.7 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.8 French Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.9 Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.10 Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.11 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.12 US Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.13 Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.14 Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), AGR (%), 2015 -2026
Figure 6.15 Biologics Market: BRIC Revenue Shares (%), 2015
Figure 6.16 Biologics Market: China Revenue Shares (%), AGR (%), 2016
Figure 6.17 Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.18 Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.19 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.20 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 6.21 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 7.1 Leading Biotech API CMOs: Mammalian Cell Culture Manufacturing Scale, 2015
Figure 7.2 Leading Biotech API CMOs: Microbial Fermentation Manufacturing Scale, 2015
Figure 7.3 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2013-2015
Figure 7.4 Celltrion: Revenue ($bn), 2009-2015
Figure 7.5DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2015
Figure 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), 2009-2015
Figure 8.1 Biosimilars Market Revenue Forecast ($bn), AGR (%), 2015-2026
Figure 10.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2016 - 2026
Figure 10.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2016, 2018, 2020, 2022, 2024 and 2026

★調査レポート[生物学的製剤API(原薬)製造サービスの世界市場予測2016-2026]販売に関する免責事項
★調査レポート[生物学的製剤API(原薬)製造サービスの世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆